Premium
Recombinant Human Growth Hormone Treatment of Children with Chronic Renal Failure: Update 1990
Author(s) -
FINE R.N.
Publication year - 1990
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1990.tb11670.x
Subject(s) - medicine , human growth hormone , chronic renal failure , recombinant dna , growth hormone , intensive care medicine , hormone , pediatrics , endocrinology , biochemistry , chemistry , gene
. Nine children with growth retardation due to chronic renal failure were treated with recombinant human growth hormone (rhGH) for 12‐36 months. Results demonstrated a significant increase in height velocity at each 12‐month interval compared with that achieved during the year prior to treatment. However, the increase in bone age was no greater than the increase in chronological age during the period of treatment. The mean calculated creatinine clearance did not decrease significantly during the 36 months of treatment; however, two patients required institution of dialysis at 18 and 30 months following initiation of rhGH treatment. There was no exacerbation of the glucose intolerance of uraemia following treatment. Currently, 6 of 7 patients who have been treated for more than 24 months have achieved sufficient acceleration in height velocity to attain an SDS of less than ‐2.00 and are above the 5th centile for chronological age on the growth curve. These updated data indicate that rhGH treatment of growth retarded children with chronic renal failure continues to result in accelerated height velocity during the second and third year of treatment, and demonstrate the potential for such children to achieve normal stature (±2 SD) for chronological age despite the continued presence of chronic renal failure.